HK Stock Market Move | BIOHEART-B(02185) rose more than 21% in the early trading session. The subsidiary-developed Iberis RDN system completed its first commercial surgery in Germany.

BIOHEART-B (02185) surged over 21% in early trading, rising 21.51% to HK$2.26 as of the time of publication, with a trading volume of HK$915,000. In terms of news, on March 3rd, BIOHEART-B announced that in February 2025, its subsidiary Shanghai Antong Medical Technology Co., Ltd. (Antong) successfully carried out the first commercial operation using the Iberis Multi-polar Renal Artery Radiofrequency Ablation System (IberisRDN system) in Germany. The operation was led by Dr. Saarraaken Kulenthiran's team at the University Hospital of Saarland. There were no reports of complications or adverse events. This case was supported by Polyacto International Group Limited (Polyacto) and Antong. As of the date of this announcement, the IberisRDN system is the only renal nerve denervation (RDN) product globally approved for use with both Transradial Artery (TRA) and Transfemoral Artery (TFA) approaches. TRA makes RDN safer, more effective, and more cost-effective. The company's ultimate goal is to provide outpatient RDN surgery for patients worldwide. Antong obtained the CE mark for the IberisRDN system in Europe in 2016 and is conducting a post-market clinical trial, "RADIUS-HTN."